Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPro1595 in Alzheimer's with Inflammation
NCT03943264Phase 1Completed
- Sponsor
- INmune Bio Inc.
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegipanermin in Alzheimer's disease (AD) (3 arms), sponsored by INmune Bio Inc. Primary endpoints: Treatment-Emergent Adverse Events at 12 weeks and Treatment-Emergent Adverse Events Rate at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
pegipanermin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03943264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943264.